Amgen Surpasses Expectations and Leads in Trading Volume with $910M Activity

Market Snapshot

On March 30, 2026, Amgen (AMGN) closed with a slight gain of 0.07%, trading at $349.00. The stock saw a trading volume of 2.39 million shares, with a daily range between $348.13 and $351.83. Notably, Amgen’s trading volume of $0.91 billion ranked it first in terms of trading activity for the day, highlighting significant investor interest. The company’s 52-week range remains between $261.43 and $391.29, and the stock maintains a market capitalization of approximately $188.14 billion.

Key Drivers

Amgen’s recent performance and trajectory are largely shaped by its robust earnings reports and ongoing developments in its drug pipeline. The company reported Q4 2025 earnings of $5.29 per share, surpassing analysts’ expectations of $4.76 by 11.84%, and revenue of $9.9 billion, exceeding the projected $9.46 billion by 4.65%. These results reflect strong underlying business momentum, particularly in its cardiometabolic and rare disease therapies. The Q4 2025 earnings report was followed by a 6.24% rise in the stock price, indicating a positive market reaction to the results. This momentum was echoed in the Q3 2025 earnings report, where the firm posted $5.64 in EPS, beating estimates by 11.9%, and revenue of $9.6 billion against expectations of $8.98 billion.

The company’s long-term guidance for FY2026, which projects non-GAAP earnings per share between $21.60 and $23.00, further underpins investor confidence. Amgen’s CEO, Bob Bradway, emphasized the potential of its late-stage drug candidate MariTide, describing it as a unique offering in the GLP-1 and weight loss space, with the potential to provide strong efficacy through monthly to quarterly dosing. This development has attracted attention from analysts, with some expressing cautious optimism about the long-term growth potential of the therapy. Jim Cramer, a prominent market commentator, highlighted Amgen as one of his "hottest GLP-1 and weight loss stock picks," reinforcing its position as a key player in the biotech sector.

The company’s strong financial performance is also supported by its consistent dividend policy. Amgen recently announced a quarterly dividend of $2.52 per share, with a forward annualized yield of 2.9%. The payout ratio of 70.84% suggests that while the dividend is generous, it is still within a sustainable range given the company’s earnings power. The dividend announcement, along with the firm’s long-standing history of increasing payouts, has likely contributed to a stable base of income-seeking investors and institutional holdings. In fact, institutional ownership of Amgen stands at approximately 76.50%, with major investors including Norges Bank, Capital World Investors, and Panagora Asset Management, all of whom have increased their stakes in the stock.

Despite its recent successes, Amgen faces challenges, including the rising costs of R&D and potential pressure on short-term margins. The company has been increasing investment in innovation and pipeline development, which could impact profitability in the near term. Additionally, while analysts generally maintain a "Hold" rating, there are mixed views on the stock. One analyst has rated it as "Strong Buy," fourteen as "Buy," thirteen as "Hold," and two as "Sell." The consensus price target of $354.60 suggests that while the stock is seen as fairly valued, it lacks immediate upside compared to other opportunities. Some analysts have noted that the stock may not be as attractively positioned as certain AI or onshoring-benefit stocks.

Looking ahead, the company is expected to release its next earnings report on April 29, 2026, with estimates of $4.8 in EPS and $8.58 billion in revenue. Given Amgen’s strong historical performance, consistent earnings beats, and robust guidance, the market will likely continue to monitor developments in its drug pipeline, particularly around MariTide, as well as any regulatory or competitive developments in the broader biotech landscape. For now, the combination of solid earnings, strategic innovation, and a strong institutional backing appears to be the primary drivers behind Amgen’s market performance.